Want to see IN:IOLCP full AI Analyst Report?
Top Page
IOL Chemicals & Pharmaceuticals Ltd.
(IOLCP)
Select Model
Select Model
Rating:64Neutral
Price Target:
₹180.00
▲(114.06% Upside)
Action:Reiterated
Date:08/27/26
The score is driven by mixed fundamentals: a conservative balance sheet is a clear positive, but weaker margin/ROE trends and volatile free cash flow reduce confidence in earnings quality. Technically, the stock has strong upward momentum and trades well above key moving averages, though indicators are somewhat stretched. Valuation is a notable headwind with a high P/E and low dividend yield.
Positive Factors
Conservative balance sheet
Very low leverage gives IOLCP financial resilience and preserves flexibility to fund operations or pursue growth without relying heavily on external financing. The sustained increase in equity further strengthens its capacity to absorb business volatility over the next several quarters.
Negative Factors
Material margin compression
The sharp decline in gross and net margins shows that earnings quality and pricing power are materially weaker than at the FY2021 peak. Persistently lower profitability could limit reinvestment, reduce returns on capital, and make earnings more sensitive to cost or mix changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage gives IOLCP financial resilience and preserves flexibility to fund operations or pursue growth without relying heavily on external financing. The sustained increase in equity further strengthens its capacity to absorb business volatility over the next several quarters.
Read all positive factors
IOL Chemicals & Pharmaceuticals Ltd. (IOLCP) vs. iShares MSCI India ETF (INDA)
Market Cap
₹53.01B
Dividend Yield0.55%
Average Volume (3M)212.91K
Price to Earnings (P/E)31.6
Beta (1Y)1.49
Revenue Growth18.56%
EPS Growth60.06%
CountryIN
Employees3,592
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)5.72
Shares Outstanding293,527,500
10 Day Avg. Volume160,256
30 Day Avg. Volume212,912
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)1.19
Price to Sales (P/S)0.92
P/FCF Ratio55.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.5
Revenue Forecast (FY)₹27.42B
IOL Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Established in 1986 and headquartered in Ludhiana, India, IOL Chemicals and Pharmaceuticals Limited operates as a global manufacturer and supplier of diverse pharmaceutical and chemical products. Its pharmaceutical portfolio encompasses a wide arr...
IOL Chemicals & Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
82
Very Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.24B | 23.19B | 20.68B | 21.19B | 22.02B | 21.84B |
| Gross Profit | 5.02B | 5.03B | 6.54B | 2.70B | 6.41B | 5.72B |
| EBITDA | 3.13B | 2.69B | 2.25B | 2.61B | 2.46B | 2.71B |
| Net Income | 1.68B | 1.38B | 1.01B | 1.34B | 1.39B | 1.68B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 25.87B | 23.82B | 22.44B | 20.22B | 19.62B |
| Cash, Cash Equivalents and Short-Term Investments | 2.00B | 2.00B | 2.09B | 1.43B | 186.40M | 1.20B |
| Total Debt | 0.00 | 1.35B | 1.17B | 327.60M | 798.10M | 439.50M |
| Total Liabilities | -17.99B | 7.88B | 6.94B | 6.33B | 5.14B | 5.70B |
| Stockholders Equity | 17.99B | 17.99B | 16.88B | 16.12B | 15.08B | 13.92B |
Cash Flow | ||||||
| Free Cash Flow | -535.70M | 384.30M | -349.30M | 159.10M | -895.50M | -602.40M |
| Operating Cash Flow | 110.60M | 2.11B | 1.79B | 2.90B | 1.22B | 930.50M |
| Investing Cash Flow | -961.60M | -2.10B | -1.54B | -1.91B | -1.20B | -1.21B |
| Financing Cash Flow | 342.30M | -145.00M | 460.40M | -925.00M | -41.10M | -16.40M |
IOL Chemicals & Pharmaceuticals Ltd. Technical Analysis
Neutral
84.09
Price Trends
191.88
Negative
170.19
Positive
127.93
Positive
Market Momentum
-6.08
Positive
44.64
Neutral
38.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:IOLCP, the sentiment is Neutral. The current price of 84.09 is below the 20-day moving average (MA) of 193.59, below the 50-day MA of 191.88, and below the 200-day MA of 127.93, indicating a neutral trend. The MACD of -6.08 indicates Positive momentum. The RSI at 44.64 is Neutral, neither overbought nor oversold. The STOCH value of 38.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:IOLCP.
IOL Chemicals & Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹256.80B | 51.47 | ― | 0.17% | 78.33% | 182.61% | |
64 Neutral | ₹53.01B | 31.58 | ― | 0.55% | 18.56% | 60.06% | |
64 Neutral | ₹208.19B | 31.06 | ― | 0.21% | 24.83% | 36.88% | |
57 Neutral | ₹40.86B | 21.39 | ― | 0.45% | 10.54% | 1.27% | |
56 Neutral | ₹24.96B | -73.76 | ― | 0.30% | -5.37% | -153.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹31.41B | 84.69 | ― | 0.45% | 27.30% | 456.80% |
* General Sector Average
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
180.60
87.27
93.50%
IN:AARTIDRUGS
Aarti Drugs Limited
447.70
-44.51
-9.04%
IN:GRANULES
Granules India Limited
840.15
270.09
47.38%
IN:HIKAL
Hikal Limited
202.40
-38.52
-15.99%
IN:NEULANDLAB
Neuland Laboratories Ltd.
20,015.65
4,669.62
30.43%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
653.40
57.65
9.68%
IOL Chemicals & Pharmaceuticals Ltd. Corporate Events
IOL Chemicals & Pharmaceuticals Clears Key Resolutions at 39th AGM
Sep 2, 2026
IOL Chemicals Pharmaceuticals Ltd. held its 39th Annual General Meeting on September 2, 2026, via video conferencing and other audio-visual means, in compliance with Indian corporate and securities regulations. Shareholders were provided remote a...
IOL Chemicals & Pharmaceuticals clears June quarter unaudited results with clean review
Aug 10, 2026
IOL Chemicals and Pharmaceuticals Limited said its board has approved the company’s standalone and consolidated unaudited financial results for the quarter ended 30 June 2026, following a meeting held on 10 August 2026. The results, which ca...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.